Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy

NCT02990611 · clinicaltrials.gov ↗
COMPLETED
Status
1087
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Bristol-Myers Squibb